Impact of biologic and targeted synthetic therapies on bone health in immune-mediated inflammatory diseases: a narrative review. (PubMed, Front Med (Lausanne)) - Sep 11, 2026 - "bDMARDs and tsDMARDs, including TNF-α inhibitors, IL-6 inhibitors, abatacept, rituximab, IL-17 inhibitors, and JAK inhibitors, generally preserve or modestly increase bone mineral density (BMD) and favorably modulate bone turnover markers (BTMs), although these effects do not always correlate with changes in BMD. bDMARDs and tsDMARDs appear to preserve or modestly improve bone mass and positively influence bone turnover in IMIDs. However, increased BMD does not consistently translate into lower fracture risk, and current evidence is insufficient to draw definitive conclusions regarding the effect of bDMARDs and tsDMARDs on fracture risk."
Journal • Review • Inflammation • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • IL17A
|
|
Ana Valeria Acosta-Alfaro; Gabriela Nataly Cueva-Nájera; Isabel De La Cámara-Fernández; Olga María Reillo-Sánchez; Santiago Muñoz-Fernández; Tatiana Cobo-Ibáñez
|